Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 3Triple Negative Breast Neoplasms 2Melanoma 2Lung Neoplasms 2Ganglioneuroblastoma 2Transplant-Related Hematologic Malignancy 1Recurrence 1Prostatic Neoplasms 1Neoplasms 1Multiple Myeloma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Locally Advanced Pancreatic Adenocarcinoma 1Leukemia, Plasma Cell 1Leukemia 1Hodgkin Disease 1Gliosarcoma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Adenoma, Islet Cell 1

Interventions

Temozolomide 40Magnetic Resonance Spectroscopy 19Radiotherapy 18Specimen Handling 14Radiation 12Bevacizumab 11Lomustine 9pembrolizumab 6fludarabine 5Surgical Procedures, Operative 5atezolizumab 4Nivolumab 4Ipilimumab 4Cyclophosphamide 4Carboplatin 4Biopsy 4cemiplimab 3azeliragon 3Immunoglobulin G 3Disulfides 3Aminolevulinic Acid 3veliparib 2trametinib 2rocakinogene sifuplasmid 2poly ICLC 2olaparib 2lutetium Lu 177 dotatate 2durvalumab 2dabrafenib 2contrast agent BR1 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × sargramostim × 90 days × Clear all
NCT02455557 2026-03-30

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Roswell Park Cancer Institute

Phase 2 Active not recruiting
66 enrolled 11 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡